SWP
STAB

Stratos Wealth Partners’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History

Stratos Wealth Partners’s Portfolio STAB Stock Details STAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-100
Closed – – 2700
2018
Q3 		$0 Buy
+100
New +$215 ﹤0.01% 3074
2018
Q2 		– Sell
-100
Closed – – 2785
2018
Q1 		$0 Hold
100
– – ﹤0.01% 3261
2017
Q4 		$0 Buy
+100
New +$304 ﹤0.01% 2850

Other funds holding STAB

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Stratos Wealth Partners's STAB Position: Q4 2018 in Review

Stratos Wealth Partners sold out of Statera Biopharma, Inc. Common Stock (STAB) in Q4 2018, closing a stake of 100 shares.

Stratos Wealth Partners first reported a position in STAB in Q4 2017 and held it in 3 quarters. The position peaked at $0 in Q3 2018. 15 funds tracked by Wall St. Rank hold STAB as of Q4 2018.

  • Stratos Wealth Partners reported no remaining Statera Biopharma, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Stratos Wealth Partners sold 100 Statera Biopharma, Inc. Common Stock shares in Q4 2018.
  • Stratos Wealth Partners first reported a position in Statera Biopharma, Inc. Common Stock in Q4 2017 and held it in 3 quarters.
  • Stratos Wealth Partners's Statera Biopharma, Inc. Common Stock position peaked at $0 in Q3 2018.
  • 15 funds tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q4 2018.

Based on Stratos Wealth Partners's 13F filing for Q4 2018, filed 8 Feb 2019.